Phio Pharmaceuticals Corp.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Phio Pharmaceuticals Corp.
Plus deals involving AbbVie/Mitokinin, Roivant/Silicon Therapeutics, CASI/Cleave Therapeutics, Tallac/ALX Oncology, AgeX/LyGenesis, Chinook/Evotec and more.
TNX-1600 joins two other candidates, including Phase III TNX-102 SL, in Tonix’s PTSD portfolio. CureVac and Yale partner on mRNA therapies for pulmonary disease.
RXi thought it had solved the RNAi delivery issue but was focused on dermatology and ophthalmology. New CEO Dispersyn thought the platform offered more lucrative promise as a way of optimizing IO therapy.
Fortress Biotech’s subsidiary will add the lentiviral gene therapy now in pair of Phase I/II trials to its pipeline. RXi partners with Karolinska to advance its self-delivering RNAi technology, while Avalon enlists Weill Cornell to enhance its CAR-T capabilities.
- Drug Delivery
- Antisense, Oligonucleotides
- Large Molecule
Drug Discovery Tools
- Molecular Diversity
- Other Names / Subsidiaries
- Apthera, Inc.
- MirImmune, Inc.
- RXi Pharmaceuticals Corp.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.